Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA.
Nat Rev Drug Discov. 2012 Oct;11(10):751-61. doi: 10.1038/nrd3801. Epub 2012 Aug 31.
A key part of drug discovery and development is the characterization and optimization of the safety and efficacy of drug candidates to identify those that have an appropriately balanced safety-efficacy profile for a given indication. The therapeutic index (TI)--which is typically considered as the ratio of the highest exposure to the drug that results in no toxicity to the exposure that produces the desired efficacy--is an important parameter in efforts to achieve this balance. Various types of safety and efficacy data are generated in vitro and in vivo (in animals and in humans), and these data can be used to predict the clinical TI of a drug candidate at an early stage. However, approaches to systematically and quantitatively compare these types of data and to apply this knowledge more effectively are needed. This article critically discusses the various aspects of TI determination and interpretation in drug development for both small molecule drugs and biotherapeutics.
药物发现和开发的一个关键部分是对候选药物的安全性和疗效进行特征描述和优化,以确定那些在特定适应症下具有适当平衡的安全性-疗效特征的药物。治疗指数(TI)--通常被认为是导致无毒性的最高药物暴露与产生所需疗效的暴露之间的比值--是实现这种平衡的重要参数。各种类型的安全性和疗效数据在体外和体内(在动物和人体中)产生,这些数据可用于在早期预测候选药物的临床 TI。然而,需要有系统地和定量地比较这些类型的数据的方法,并更有效地应用这些知识。本文批判性地讨论了小分子药物和生物治疗药物开发中 TI 确定和解释的各个方面。